Sarepta Therapeutics Inc (SRPT)
Profitability ratios
Return on sales
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Gross profit margin | 58.68% | 51.26% | 58.99% | 41.02% | 24.99% |
| Operating profit margin | -21.54% | -57.47% | -65.50% | -104.46% | -185.27% |
| Pretax margin | -41.83% | -73.95% | -59.69% | -102.40% | -187.45% |
| Net profit margin | -43.11% | -75.40% | -59.66% | -102.60% | -187.77% |
Sarepta Therapeutics Inc's profitability ratios have shown significant fluctuations over the past five years. The company's gross profit margin has generally improved, indicating that the company has been able to increase its revenue while managing its cost of goods sold efficiently. However, the operating profit margin, pretax margin, and net profit margin have all been negative in each of the past five years, indicating that the company has struggled to generate a consistent profit from its operations.
The operating profit margin has shown some improvement over the years, moving from deeply negative values to closer to breakeven in 2023. This could indicate that the company is becoming more efficient in managing its operating expenses. However, the pretax margin and net profit margin continue to show significant losses, with the net profit margin exceeding 40% in the most recent year.
Overall, Sarepta Therapeutics Inc's profitability ratios suggest that while the company has improved its gross profit margin and operating efficiency, it still faces challenges in generating a profit at the pretax and net levels. Investors and stakeholders may want to closely monitor the company's efforts to control expenses and drive revenue growth in order to improve overall profitability in the future.
Return on investment
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -8.20% | -17.14% | -14.60% | -18.90% | -38.71% |
| Return on assets (ROA) | -16.42% | -22.49% | -13.30% | -18.57% | -39.23% |
| Return on total capital | -25.01% | -33.00% | -17.55% | -28.11% | -45.54% |
| Return on equity (ROE) | -62.37% | -182.75% | -45.13% | -72.74% | -87.40% |
Sarepta Therapeutics Inc's profitability ratios indicate a varying level of performance over the past five years.
- The Operating return on assets (Operating ROA) has shown fluctuations with a negative trend, suggesting inefficiency in generating profits from its assets in recent years.
- Return on assets (ROA) has also been negative, indicating that the company has not been effective in generating profits from its total assets.
- Return on total capital has exhibited a consistent negative trend, reflecting the challenge in generating returns from the total capital employed.
- Return on equity (ROE) has been highly volatile, with significant negative values, indicating a struggle to generate profits for its equity shareholders.
Overall, the profitability ratios demonstrate a concerning performance trend for Sarepta Therapeutics Inc, highlighting the need for strategic improvements to enhance profitability and efficiency in utilizing assets and capital.